Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN.
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA.
Int Forum Allergy Rhinol. 2021 Jul;11(7):1047-1055. doi: 10.1002/alr.22756. Epub 2020 Dec 19.
Surgeons commonly prescribe prophylactic antibiotics after endoscopic sinus surgery (ESS), yet minimal data exist to support this practice. In this study we aimed to assess the impact of post-ESS antibiotics on infection, quality of life (QOL), and endoscopic scores.
This was a randomized, double-blind, placebo-controlled, noninferiority trial comparing amoxicillin-clavulanate vs placebo after ESS (NCT01919411, ClinicalTrials.gov). Adults (N = 77) with chronic rhinosinusitis (CRS) refractory to appropriate medical therapy who underwent ESS were randomized to antibiotics (N = 37) or placebo (N = 40) and followed clinically (mean ± standard deviation: 1.3 ± 0.3 and 8.8 ± 3.9 weeks postoperatively). At baseline and follow-up, QOL was measured with 22-item Sino-Nasal Outcome Test questionnaires and Lund-Kennedy endoscopic scores were evaluated. Outcomes were analyzed with repeated-measures analysis of variance and analysis of covariance and z tests for proportions.
Placebo was noninferior to antibiotic prophylaxis with regard to postoperative SNOT-22 scores (β = 0.18, 2-tailed p < 0.05). There were no significant differences between the antibiotic and placebo groups in LK score trajectories over time (p = 0.63) or in postoperative infection rates (2.6% vs 2.4%, respectively; p = 0.96). The rate of diarrhea was significantly higher in the antibiotic group (24.3% vs 2.5%; relative risk = 10.8; p = 0.02).
Although statistically underpowered, the results suggest placebo was noninferior to prophylactic antibiotics after ESS for CRS regarding postoperative sinonasal-specific QOL. There were no significant differences in postoperative endoscopic scores or rates of infection, but the rate of diarrhea was significantly higher in the antibiotic group. These findings add to the growing evidence that routine use of prophylactic postoperative antibiotics does not improve outcomes post-ESS and significantly increases the rate of diarrhea.
外科医生通常在鼻内镜鼻窦手术后(ESS)预防性使用抗生素,但支持这种做法的数据很少。在这项研究中,我们旨在评估 ESS 后使用抗生素对感染、生活质量(QOL)和内镜评分的影响。
这是一项随机、双盲、安慰剂对照、非劣效性试验,比较了 ESS 后使用阿莫西林克拉维酸与安慰剂(NCT01919411,ClinicalTrials.gov)。接受 ESS 的慢性鼻-鼻窦炎(CRS)伴药物治疗无效的成年人(N=77)被随机分为抗生素组(N=37)或安慰剂组(N=40),并在术后临床随访(平均±标准差:1.3±0.3 和 8.8±3.9 周)。在基线和随访时,使用 22 项 Sino-Nasal Outcome Test 问卷测量 QOL,评估 Lund-Kennedy 内镜评分。使用重复测量方差分析和协方差分析以及比例 z 检验分析结果。
安慰剂在术后 SNOT-22 评分方面不劣于抗生素预防(β=0.18,双侧 p<0.05)。抗生素组和安慰剂组的 LK 评分轨迹随时间的变化没有显著差异(p=0.63),或术后感染率(分别为 2.6%和 2.4%;p=0.96)。抗生素组腹泻发生率显著高于安慰剂组(24.3%比 2.5%;相对风险=10.8;p=0.02)。
尽管统计效力不足,但结果表明,对于 CRS 患者,ESS 后安慰剂与预防性抗生素相比在术后鼻-鼻窦特异性 QOL 方面不劣效。术后内镜评分或感染率无显著差异,但抗生素组腹泻发生率显著升高。这些发现增加了越来越多的证据表明,常规使用预防性术后抗生素并不能改善 ESS 后的结果,并且显著增加腹泻的发生率。